You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 21, 2025

CLINICAL TRIALS PROFILE FOR LOTEPREDNOL ETABONATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Loteprednol Etabonate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00366691 ↗ Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation Completed Medical University of South Carolina Phase 4 2006-02-01 The purpose of this study is to compare the effectiveness of Acular LS® and Lotemax® in the prevention of inflammation in the eye after cataract surgery. Acular LS is made by Allergan, Inc. It is a nonsteroidal anti-inflammatory drug (NSAID) and is approved by the Food and Drug Administration (FDA) for use following cataract surgery. Lotemax is made by Bausch & Lomb. It is a steroid and is also approved by the FDA for use following cataract surgery.
NCT00420628 ↗ Pediatric Zylet Safety and Efficacy Study Completed Bausch & Lomb Incorporated Phase 4 2006-11-01 A multicenter study to evaluate the safety and efficacy of Zylet compared to vehicle in children aged 0-6 for the management of lid inflammation (chalazion/hordeolum)
NCT00447577 ↗ Zylet vs TobraDex in Blepharokeratoconjunctivitis Completed Bausch & Lomb Incorporated Phase 4 2007-01-01 The objective of this study is to evaluate the safety and efficacy of Zylet vs. Tobradex in the treatment of ocular inflammation associated with blepharokeratoconjunctivitis
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Loteprednol Etabonate

Condition Name

Condition Name for Loteprednol Etabonate
Intervention Trials
Pain 5
Inflammation 5
Dry Eye 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Loteprednol Etabonate
Intervention Trials
Inflammation 13
Cataract 9
Dry Eye Syndromes 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Loteprednol Etabonate

Trials by Country

Trials by Country for Loteprednol Etabonate
Location Trials
United States 127
Korea, Republic of 2
Singapore 2
Israel 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Loteprednol Etabonate
Location Trials
California 12
New York 11
Ohio 7
Missouri 7
Indiana 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Loteprednol Etabonate

Clinical Trial Phase

Clinical Trial Phase for Loteprednol Etabonate
Clinical Trial Phase Trials
Phase 4 16
Phase 3 14
Phase 2 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Loteprednol Etabonate
Clinical Trial Phase Trials
Completed 41
Withdrawn 2
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Loteprednol Etabonate

Sponsor Name

Sponsor Name for Loteprednol Etabonate
Sponsor Trials
Bausch & Lomb Incorporated 22
Kala Pharmaceuticals, Inc. 8
Second Affiliated Hospital of Nanchang University 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Loteprednol Etabonate
Sponsor Trials
Industry 36
Other 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Loteprednol Etabonate: Clinical Trials, Market Analysis, and Projections

Introduction

Loteprednol etabonate is a corticosteroid widely used in ophthalmic formulations to treat various eye conditions, including postoperative inflammation, dry eye disease, and acute ocular pain. This article provides an in-depth look at the clinical trials, market analysis, and future projections for this drug.

Mechanism of Action

Loteprednol etabonate works by inhibiting the inflammatory response to various inciting agents. It reduces edema, fibrin deposition, capillary dilation, leukocyte migration, and other processes associated with inflammation. The drug also inhibits prostaglandin production, which is a key mediator of inflammation[4].

Clinical Trials

Postoperative Inflammation

Clinical trials for LOTEMAX SM (loteprednol etabonate ophthalmic gel 0.38%) have shown its efficacy in treating postoperative inflammation and pain following ocular surgery. These trials demonstrated that LOTEMAX SM, with its submicron particle size, dissolves faster in tears and provides double the penetration to the aqueous humor compared to the earlier formulation, LOTEMAX Gel (0.5%)[3].

Dry Eye Disease

For EYSUVIS (loteprednol etabonate ophthalmic suspension 0.25%), clinical trials such as STRIDE 3 (KPI-121-C-011) were conducted to demonstrate its superiority over the vehicle in treating the signs and symptoms of dry eye disease. These trials showed that EYSUVIS was effective in reducing conjunctival hyperemia and other symptoms of dry eye disease, with the clinical benefits outweighing the potential adverse effects when used for short-term treatment[4].

Acute Ocular Pain

INVELTYS (loteprednol etabonate/KPI-121) has been studied for its efficacy in treating acute ocular pain. Clinical trials have provided detailed information on trial interventions, endpoints, and status, contributing to a comprehensive understanding of INVELTYS's efficacy and safety profile. These trials have supported the use of INVELTYS as a cutting-edge treatment for acute ocular pain[5].

Safety Profile

The safety profile of loteprednol etabonate has been evaluated in various clinical trials. No deaths were reported in any of the clinical trials for EYSUVIS or LOTEMAX SM. However, some nonfatal serious adverse events were noted, such as aphakic glaucoma in a few cases. The potential serious adverse events associated with the use of topical ophthalmic corticosteroids can be minimized with appropriate slit lamp examinations and dosing limitations[1][4].

Market Analysis

Global Market

The global loteprednol etabonate market is expected to grow significantly over the next decade. Market research reports forecast that the market will expand due to increasing healthcare spending and the need for advanced therapeutic options. The report by Market Research Reports provides a detailed analysis of the global market, including data on manufacturers, regions, types, and applications, forecasting the market up to 2030[2].

United States Market

In the United States, LOTEMAX SM and INVELTYS are expected to dominate the market for postoperative pain and acute ocular pain, respectively. The market assessment for LOTEMAX SM includes forecasted sales data from 2022 to 2032, highlighting its potential in the treatment of postoperative inflammation and pain. Similarly, INVELTYS is projected to dominate the acute ocular pain sector, driven by its efficacy and the increasing demand for advanced therapies[3][5].

Market Projections

Forecasted Sales

The forecasted sales data for LOTEMAX SM and INVELTYS indicate a strong growth trajectory. For LOTEMAX SM, the market is expected to grow steadily from 2022 to 2032, driven by its advanced formulation and higher penetration into the aqueous humor. INVELTYS is also projected to see significant growth, driven by its effectiveness in treating acute ocular pain and the anticipated increase in healthcare spending[3][5].

Competitive Landscape

The competitive landscape for loteprednol etabonate includes other emerging therapies in the ophthalmic sector. INVELTYS, for example, faces competition from other treatments for acute ocular pain, but its unique formulation and clinical efficacy are expected to give it a competitive edge. The SWOT analysis included in market reports provides insights into the strengths, weaknesses, opportunities, and threats for these drugs, helping stakeholders understand the market dynamics[5].

Determining Factors for Market Growth

Increasing Healthcare Spending

The anticipated increase in healthcare spending is a significant factor driving the growth of the loteprednol etabonate market. As healthcare systems invest more in advanced therapeutic options, the demand for effective treatments like LOTEMAX SM and INVELTYS is expected to rise[5].

Advanced Therapeutic Research

Continuous research and development in ophthalmic treatments are another key factor. The development of new formulations, such as the submicron particle size in LOTEMAX SM, enhances the drug's efficacy and patient compliance, contributing to market growth[3].

Key Takeaways

  • Loteprednol etabonate is a versatile corticosteroid used in various ophthalmic formulations.
  • Clinical trials have demonstrated its efficacy in treating postoperative inflammation, dry eye disease, and acute ocular pain.
  • The safety profile is generally favorable, with appropriate monitoring and dosing limitations.
  • The global and U.S. markets for loteprednol etabonate are expected to grow significantly due to increasing healthcare spending and advanced therapeutic research.
  • LOTEMAX SM and INVELTYS are projected to dominate their respective markets due to their clinical efficacy and unique formulations.

FAQs

What is the mechanism of action of loteprednol etabonate?

Loteprednol etabonate inhibits the inflammatory response by reducing edema, fibrin deposition, capillary dilation, and other inflammatory processes. It also inhibits prostaglandin production.

What are the common indications for loteprednol etabonate?

Common indications include postoperative inflammation and pain following ocular surgery, dry eye disease, and acute ocular pain.

What are the key differences between LOTEMAX SM and LOTEMAX Gel?

LOTEMAX SM has a submicron particle size that dissolves faster in tears and provides double the penetration to the aqueous humor compared to LOTEMAX Gel.

What are the potential serious adverse events associated with loteprednol etabonate?

Potential serious adverse events include aphakic glaucoma and other steroid-related side effects, which can be minimized with appropriate slit lamp examinations and dosing limitations.

What is the forecasted market growth for loteprednol etabonate?

The market is expected to grow significantly over the next decade, driven by increasing healthcare spending and advanced therapeutic research.

Sources

  1. FDA Clinical Review: CLINICAL REVIEW of NDA 202872/S-002 - FDA.
  2. Market Research Reports: Global Loteprednol Etabonate Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030.
  3. GlobeNewswire: United States LOTEMAX SM (Loteprednol Etabonate Ophthalmic Gel) Drug Market Insights and Forecast Report 2022-2032.
  4. FDA Clinical Review: 210933Orig1s000 CLINICAL REVIEW(S) - accessdata.fda.gov.
  5. GlobeNewswire: INVELTYS (loteprednol etabonate/KPI-121) Drug Insight and U.S. Market Analysis 2023-2032.
Last updated: 2025-01-01

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.